Skip to main content
. Author manuscript; available in PMC: 2019 Mar 26.
Published in final edited form as: Ocul Surf. 2018 Jul 7;16(4):463–469. doi: 10.1016/j.jtos.2018.07.004

Fig. 5.

Fig. 5.

Effect of PPARγ signaling on mRNA expressions of ADFP, PPARγ, ELOVL4, and FABP4 in hMGEC (A–D) and in hTCEpi (E–H). Rosiglitazone significantly upregulated expression of (A) ADFP, (B) PPARγ, (C) ELOVL4, and (D) FABP4 by 9.6, 2.7, 2.6, and 3.3 folds on average, respectively (all P < 0.05 except for FABP4, P = 0.057) in hMGEC. A PPARγ antagonist T0070907 significantly abrogated rosiglitazone-induced upregulation of these genes to the similar level with control group when treated prior to rosiglitazone treatment. (E–H) This PPARγ responsive regulation was not observed in hTCEpi. Rosiglitazone increased mRNA of ADFP (#: P = 0.027), but this upregulation was not suppressed by T0070907 (A–D; n = 9 and E–H; n = 6).